GMAB – Genmab A/S
Genmab A/SGMAB
$32.93Name : Genmab A/S
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $20,269,938,688.00
EPSttm : 1.93
Genmab A/S
$32.93
1.14%$0.38Float Short %
0.57
Margin Of Safety %
2
Put/Call OI Ratio
0.3
EPS Next Q Diff
-0.15
EPS Last/This Y
-0.03
EPS This/Next Y
-0.21
Price
33.34
Target Price
33.64
Analyst Recom
1.69
Performance Q
56.75
Relative Volume
3.14
Beta
0.96
Ticker: GMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | GMAB | 27.55 | 0.30 | 0.75 | 1957 |
| 2025-09-09 | GMAB | 27.84 | 0.30 | 0.21 | 1958 |
| 2025-09-10 | GMAB | 27.72 | 0.34 | 0.07 | 2014 |
| 2025-09-11 | GMAB | 28.63 | 0.34 | 0.06 | 2019 |
| 2025-09-12 | GMAB | 27.81 | 0.34 | 0.06 | 2003 |
| 2025-09-15 | GMAB | 27.99 | 0.34 | 0.78 | 2002 |
| 2025-09-16 | GMAB | 28.22 | 0.34 | 0.00 | 2013 |
| 2025-09-17 | GMAB | 28.08 | 0.34152823920266 | 0 | 2019 |
| 2025-09-18 | GMAB | 28.04 | 0.34 | 0.19 | 2020 |
| 2025-09-19 | GMAB | 28.28 | 0.34 | 0.00 | 1985 |
| 2025-09-22 | GMAB | 28.6 | 0.34 | 0.10 | 1797 |
| 2025-09-23 | GMAB | 28.74 | 0.34 | 0.12 | 1798 |
| 2025-09-24 | GMAB | 29.45 | 0.34 | 0.56 | 1830 |
| 2025-09-25 | GMAB | 28.84 | 0.34 | 3.33 | 1843 |
| 2025-09-26 | GMAB | 29.11 | 0.33 | 0.00 | 1832 |
| 2025-09-29 | GMAB | 29.33 | 0.33 | 0.01 | 1838 |
| 2025-09-30 | GMAB | 30.66 | 0.32 | 0.00 | 1853 |
| 2025-10-01 | GMAB | 31.77 | 0.31 | 0.30 | 1901 |
| 2025-10-02 | GMAB | 32.12 | 0.32 | 0.63 | 2089 |
| 2025-10-03 | GMAB | 33.56 | 0.34 | 0.04 | 2140 |
| 2025-10-06 | GMAB | 33.3 | 0.30 | 0.01 | 2373 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | GMAB | 27.54 | 58.3 | 168.4 | 1.68 |
| 2025-09-09 | GMAB | 27.85 | 58.3 | 200.6 | 1.68 |
| 2025-09-10 | GMAB | 27.72 | 58.3 | 168.0 | 1.68 |
| 2025-09-11 | GMAB | 28.61 | 58.3 | 219.0 | 1.68 |
| 2025-09-12 | GMAB | 27.81 | 58.3 | 107.1 | 1.68 |
| 2025-09-15 | GMAB | 27.99 | 58.3 | 142.8 | 1.68 |
| 2025-09-16 | GMAB | 28.24 | 58.3 | 182.1 | 1.68 |
| 2025-09-17 | GMAB | 28.08 | 58.3 | 174.9 | 1.68 |
| 2025-09-18 | GMAB | 28.05 | 58.3 | 175.1 | 1.68 |
| 2025-09-19 | GMAB | 28.28 | 58.3 | 183.6 | 1.68 |
| 2025-09-22 | GMAB | 28.60 | 58.3 | 179.8 | 1.68 |
| 2025-09-23 | GMAB | 28.74 | 58.3 | 181.7 | 1.68 |
| 2025-09-24 | GMAB | 29.46 | 58.3 | 197.6 | 1.68 |
| 2025-09-25 | GMAB | 28.84 | 58.3 | 114.9 | 1.68 |
| 2025-09-26 | GMAB | 29.07 | 58.3 | 203.5 | 1.68 |
| 2025-09-29 | GMAB | 29.33 | 58.3 | 235.2 | 1.68 |
| 2025-09-30 | GMAB | 30.66 | 58.3 | 300.5 | 1.68 |
| 2025-10-01 | GMAB | 31.77 | 56.8 | 268.1 | 1.67 |
| 2025-10-02 | GMAB | 32.04 | 56.8 | 156.8 | 1.67 |
| 2025-10-03 | GMAB | 33.57 | 56.8 | 232.3 | 1.67 |
| 2025-10-06 | GMAB | 33.34 | 56.8 | 219.2 | 1.67 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | GMAB | 0 | -0.21 | 0.56 |
| 2025-09-09 | GMAB | 0 | -0.21 | 0.56 |
| 2025-09-10 | GMAB | 0 | -0.21 | 0.56 |
| 2025-09-11 | GMAB | 0 | -0.21 | 0.63 |
| 2025-09-12 | GMAB | 0 | -0.21 | 0.63 |
| 2025-09-15 | GMAB | 0 | -0.20 | 0.63 |
| 2025-09-16 | GMAB | 0 | -0.20 | 0.63 |
| 2025-09-17 | GMAB | 0 | -0.20 | 0.63 |
| 2025-09-18 | GMAB | 0 | -0.20 | 0.63 |
| 2025-09-19 | GMAB | 0 | -0.20 | 0.63 |
| 2025-09-22 | GMAB | 0 | -0.26 | 0.63 |
| 2025-09-23 | GMAB | 0 | -0.26 | 0.63 |
| 2025-09-24 | GMAB | 0 | -0.26 | 0.63 |
| 2025-09-25 | GMAB | 0 | -0.26 | 0.57 |
| 2025-09-26 | GMAB | 0 | -0.26 | 0.57 |
| 2025-09-29 | GMAB | 0 | -0.26 | 0 |
| 2025-09-30 | GMAB | 0 | -0.26 | 0.57 |
| 2025-10-01 | GMAB | 0 | -0.26 | 0.57 |
| 2025-10-02 | GMAB | 0 | -0.26 | 0.57 |
| 2025-10-03 | GMAB | 0 | -0.26 | 0.57 |
| 2025-10-06 | GMAB | 0 | -0.19 | 0.57 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.54
Avg. EPS Est. Current Quarter
0.45
Avg. EPS Est. Next Quarter
0.39
Insider Transactions
Institutional Transactions
-0.19
Beta
0.96
Average Sales Estimate Current Quarter
6217
Average Sales Estimate Next Quarter
6651
Fair Value
33.86
Quality Score
100
Growth Score
96
Sentiment Score
100
Actual DrawDown %
32.1
Max Drawdown 5-Year %
-63.1
Target Price
33.64
P/E
16.63
Forward P/E
19.23
PEG
1.66
P/S
6.05
P/B
3.86
P/Free Cash Flow
20.4
EPS
2
Average EPS Est. Cur. Y
1.67
EPS Next Y. (Est.)
1.46
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
37.52
Relative Volume
3.14
Return on Equity vs Sector %
-1.9
Return on Equity vs Industry %
11.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.06
EBIT Estimation
219.2
Genmab A/SSector: Healthcare
Industry: Biotechnology
Employees: 2639
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading